P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension
B E Sands(Icahn School of Medicine at Mount Sinai), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Ramesh Arasaradnam(University Hospital Coventry), Rupert W. Leong(The University of Sydney), Yiying Zhou(Janssen (United States)), Tadakazu Hisamatsu(Kyorin University), Silvio Danese(IRCCS Ospedale San Raffaele), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), H Zhang(Janssen (United States)), Chris O’Brien(Neurocrine Biosciences (United States)), Ellen Scherl(NewYork–Presbyterian Hospital), Jewel Johanns(Johnson & Johnson (United States)), María T. Abreu(Icahn School of Medicine at Mount Sinai)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k